CoChat

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.

Hong, David S., Morris, Van Karlyle, Fu, Siqing, Overman, Michael J., Piha-Paul, Sarina Anne, Kee, Bryan K., Zinner, Ralph, Fogelman, David R., Mistry, Reena, Shureiqi, Imad, Meric-Bernstam, Funda, Kopetz, Scott · 2014 · Journal of Clinical Oncology
Cited by 28

The DOI matches its Crossref record.

Abstract

3516 Background: BRAF V600 mutations, present in 5-10% of patients (pts) with metastatic colorectal cancer (mCRC), are considered poor prognostic markers, and <10% of BRAF-mutated mCRC pts respond to a combination of cetuximab (C) and irinotecan (I). Vemurafenib (V), an oral kinase inhibitor to the mutated V600 isoform of BRAF, demonstrated a 5% response rate in a phase I trial with BRAF-mutated mCRC. In vitro data in CRC cell lines has shown that blockade of mutated BRAF by vemurafenib triggers compensatory activation of EGFR. Inhibition of EGFR combined with vemurafenib results in synergistic cytotoxicity in preclinical models, further augmented by irinotecan. The safety and efficacy of the combination in pts with BRAF-mutated advanced malignancies have not been studied. Methods: In this 3+3 phase I study, pts with refractory BRAF-mutated cancer received escalating doses of vemurafenib in combination with cetuximab and irinotecan over a 14-day cycle. Radiographic responses were evaluated every 4 cycles by RECIST 1.1. Adverse events (AEs) were assessed by CTCAE 4.0. Results: Through 1/2014, 10 pts have been enrolled: 7 at dose level 1(DL) (V- 480mg PO BID, C-250 mg/m2 weekly and I- 180mg/m2 every 14 days) and three at DL 2 (increased to V-720mg PO BID). One dose-limiting toxicity was observed at DL1 (grade 3 arthralgia) and resolved with dose reduction. The most common AEs were rash, nausea, and diarrhea. Of the 6 evaluable pts treated at DL 1, 5 had mCRC and 1 had appendiceal adenocarcinoma. Four of the 5 mCRC pts (80%) achieved a partial response. For the 5 mCRC pts, median best response was a reduction of -44% (range, 0% to -70%) with duration of responses of 5, 5+, 8+, 12+, and 14+ cycles. The appendiceal carcinoma pt had disease progression. PK and PD analysis is planned. Conclusions: The combination of vemurafenib with irinotecan and cetuximab seems well tolerated in pts with BRAF-mutated mCRC. Even with a low vemurafenib dose, PRs were seen in 4 of 5 evaluable mCRC pts in the first cohort. Additional pts continue to be enrolled at higher dose levels of vemurafenib. A US cooperative group randomized phase II trial of this combination in BRAF-mutated mCRC (SWOG1406) is planned. Clinical trial information: NCT01787500.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.3516

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 28

Metadata

Authors
Hong, D. S., Morris, V. K., Fu, S., Overman, M. J., Piha-Paul, S. A., Kee, B. K., Zinner, R., Fogelman, D. R., Mistry, R., Shureiqi, I., Meric-Bernstam, F., & Kopetz, S.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
3516-3516
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2531555720
Cited by
28
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3516
The paper
Hong, D. S., Morris, V. K., Fu, S., Overman, M. J., Piha-Paul, S. A., Kee, B. K., Zinner, R., Fogelman, D. R., Mistry, R., Shureiqi, I., Meric-Bernstam, F., & Kopetz, S. (2014). Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.